Cruise line offers pediatric telemedicine

Laura Pedulli | | Health Exec | Precision Medicine

All aboard for telemedicine! MSC Cruises has become the first cruise line to offer guests 24/7 multilingual pediatric telemedicine service on board.

The cruise line, which is partnering with Italian-based Giannina Gaslini Institute, will install telemedicine technology across its entire fleet to enable “ship-to-shore care,” according to a press release.

Physicians will be able to consult specialist pediatricians at any time to seek a second opinion or carry out procedures such as remote diagnosis, radiology and monitoring.

"Pediatric telemedicine is an addition to other existing services on our ships, such as teleradiology and teleconsultation, for a cruise vacation where we can respond to any need,” said Gianni Onorato, director general of the Giannina Gaslini Institute, in a statement.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.